LULorena Usero

Lorena Usero

*This is an algorithmically generated author record based on publicly available information.

Lorena Usero has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The ER stress inducer ABTL0812/ibrilatazar potentiates standard chemotherapies and mitigates the immunosuppressive microenvironment in preclinical models of pancreatic cancer

    by Lorena Usero, Guillermo Yoldi, Claudia Faundez-Vidiella, Nora Dieguez-Martinez, Sandra Barbosa, Maria Viñas-Casas, Maria Arbat, Elisabet Megias-Roda, Pere J. Fabregas, Estefania Contreras, et al.

    Acquired chemoresistance is common in advanced pancreatic cancer (PCa), highlighting the need to improve the efficacy of current chemotherapy regimens. In this study, we investigated the first-in-class molecule ABTL0812 (Ibrilatazar), a potent inducer of endoplasmic reticulum (ER) stress currently in clinical trial for advanced PCa, as a strategy to improve the effectiveness of standard chemotherapy.ABTL0812 enhanced the efficacy of standard chemotherapies FOLFIRINOX and gemcitabine/nab-paclitaxel in a panel of pancreatic ductal adenocarcinoma cell lines and tumor xenografts, and combined treatments showed increased levels of ER stress. ABTL0812, alone or in combination with FOLFIRINOX exerted immunomodulatory effects in the KRAS/TP53 (KPC) genetically engineered mice, by impairing the intratumoral infiltration of T regulatory (Treg) cells, the major immunosuppressive cell subset in the PCa tumors. In engrafted syngeneic PCa tumors, ABTL0812 treatment, alone or in combination with FOLFIRINOX, impaired the infiltration of Treg cells, myeloid-derived suppressor cells and exhausted CD4+/CD8+ T cells. Mechanistically, we show that ABTL0812 inhibits the differentiation of CD4+ naïve T cells into Treg cells induced by TGFb. ABTL0812 also impairs the protumoral activity of stromal cells of PCa, by inhibiting the secretion of TGFb from pancreatic stellate cells levels and of the Treg cell chemoattractant CXCL12 from patient-derived pancreatic CAFs. This work establishes that ER stress inducers such as ABTL0812 potentiate the anticancer activity of the standard chemotherapy regimens currently used in PCa, and suggests their potential to improve the effectiveness of immunotherapy.